



Centre hospitalier
universitaire
de Sherbrooke



**Press Release
For immediate circulation**

**Servier Canada Inc. and the CHUS Foundation participate
In the acquisition of an endovascular ultrasonography unit**

Sherbrooke, Friday, April 3rd, 2009 – A \$100 000 donation from Servier Canada Inc., a pharmaceutical company and an investment by the CHUS Foundation have enabled the Centre hospitalier universitaire de Sherbrooke (CHUS) to acquire an endovascular ultrasonography unit. This system will ensure continuing care with cutting edge technology, permitting patients to receive complementary exams in addition to conventional coronarography diagnostic exams.

« Thanks to ultrasounds, the endovascular ultrasonography generates images in high resolution and in real time, of the complete and detailed anatomy of the artery wall. This technique lets us visualize and determine the composition of the atherosclerotic plates as well as their severity » mentioned Dr. Michel Nguyen, Medical Chief of the cardio-pulmonary customer care program at the CHUS. As well the endovascular ultrasonography is sometimes used in the vascular endoprosthesis procedure (insertion of a small metal piece resembling a coil spring, into the blood vessel) in order to verify the proper installation of the endoprosthesis.

« For Servier Canada Inc., the objective of this donation was to facilitate continuing specialized care in medical imagery for patients needing this type of procedure » indicated Philippe Etorre, Chief Executive Officer of Servier Canada.

« We are very proud that this device is available to our patients needing this treatment. For the CHUS, this represents an indispensable diagnostic tool, taking into consideration the supra regional role the center holds in cardiology and the importance in terms of research, teaching and the evaluation of technologies and health intervention as a university hospital» commented Patricia Gauthier, General Manager of the CHUS.

Every year at the CHUS – Fleurimont Hospital, between 50 and 100 patients will benefit from this procedure which will clarify their clinical situation and as such, will enable the adoption of the best treatment possible or to better define the different scenarios leading to coronary intervention.

About the Centre hospitalier universitaire de Sherbrooke (CHUS)

The Centre hospitalier universitaire de Sherbrooke consists of two establishments: the CHUS – Fleurimont Hospital and the CHUS – Hôtel-Dieu. Four facets comprise its mission: health care, teaching, research and the evaluation of technologies and methods of intervention with regards to healthcare. It is the fourth largest medical center in Quebec and is part of the Réseau universitaire intégré de santé (RUIS) at Université de Sherbrooke.

A community hospital for the population of Sherbrooke, of the Haut-Saint-François, Val-Saint-François and Coaticook regions, the CHUS offers healthcare, specialised and highly specialised services to the entire Eastern Townships population. The center also serves the Centre-du-Québec and Montérégie regions for certain highly specialised treatments in surgery, cardiology, paediatrics, obstetrics and gynaecology, neonatology, trauma, psychiatry and specialised medicine. The CHUS distinguish itself in several cutting edge specialties such as: radio surgery by gamma scalpel, positron emission tomography (PET), interventional angiography and a neuro-oncology.

At the forefront of current health care issues, the Centre de recherche clinique Étienne-Le Bel of the CHUS stands out with its integrated approach by combining fundamental clinical, epidemiological and evaluative research. Its 167 researchers combine knowledge and expertise as they aim for a common objective: to develop new knowledge to maintain healthcare, prevent diseases and to improve treatments for patients.

Close to 9 000 people are part of the CHUS hospital community: employees, doctors, researchers, professors, students, trainees and volunteers.

<http://www.chus.qc.ca>

About the CHUS Foundation

The CHUS foundation receives donations from the general public and the business community in order to contribute to the development of the CHUS, to buy equipment, to invest in research and to improve patients' well-being through the day-to-day work of the healthcare staff and doctors. It is one of the best performing foundations in Quebec. Each year, over 100 fundraising activities are organised. More than 600 volunteers, of whom 21 are board members, 64 are governors (friends and volunteers who are part of the corporation), 102 are ambassadors (representing the foundation in their respective circles), 29 are grand ambassadors (highly recognised), numerous members of the CHUS staff and other external active community members, all participate in these activities.

About Servier Canada Inc.

Servier Canada Inc. (www.servier.ca) is a pharmaceutical company based in Laval, Quebec. Present since 1978, the company's activities focus on the research and development of ethical pharmaceutical products.

Servier Canada Inc. is the Canadian affiliate of The Servier Research Group, the leading French independent pharmaceutical company and the second French pharmaceutical company worldwide. Its affiliates are present in 140 countries and account for 20,000 employees including 3,000 in research and development.

- 30 -

Information

Catherine Roy, information agent
Communications and Public Affairs Department
Centre hospitalier universitaire de Sherbrooke
Office: 819 346-1110, extension 22534
Cellular: 819 829-0955